Drugs / CR8020
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02015533 | Dec 2013 → Jan 2014 | — | Janssen Pharmaceutical K.K. | Withdrawn | No outcome recorded |
| Phase 1 | NCT01756950 | Jan → Nov 2013 | influenza | Crucell Holland BV | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01992276 | Dec 2013 → Oct 2014 | influenza | Crucell Holland BV | Withdrawn | No outcome recorded |
| Phase 2 | NCT01938352 | Oct 2013 → Jan 2014 | influenza | Crucell Holland BV | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CR8020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02015533 ↗ |
| Modality | Monoclonal antibody | “CR8020, a monoclonal antibody against influenza A viruses” NCT01756950 ↗ |
| Route | Intravenous | “administered as a single 2-hour intravenous infusion” NCT01756950 ↗ |